Beta Amyloid 2: Tau-lectric Boogaloo The antib
Post# of 148168
Quote:
The antibody targets aggregated forms of β-amyloid found in the brains of people with Alzheimer's disease, in the hopes of reducing its buildup.[3] Biogen halted development of the drug in March 2019 after preliminary data from two phase III trials suggested it would not meet the primary endpoint.[4][5][6]